Evidence map›Paper›PMID 40192445›Full record

ArticleAdvanced healthcare materials2025

Biomimetic Glycosaminoglycan-Analog Hydrogel for Improved Embolization of Aneurysms: Environment-Selective Swelling.

Sarit S Sivan, Iris Bonshtein, Maria Khoury, Yevgeniy Kreinin, Dmitry Korneyev, Tirosh Mekler, Sumaya Kaiyal, Iris Sonia Weitz, Netanel Korin

Abstract read
In one paragraph

Article in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sarit S SivanDepartment of Biotechnology Engineering, Braude College of Engineering, Karmiel, 2161002, Israel.
Iris BonshteinDepartment of Biotechnology Engineering, Braude College of Engineering, Karmiel, 2161002, Israel.
Maria KhouryDepartment of Biomedical Engineering, Technion-Israel Institute of Technology, Haifa, 32000, Israel.ORCID 0009-0009-0377-1103
Yevgeniy KreininDepartment of Biomedical Engineering, Technion-Israel Institute of Technology, Haifa, 32000, Israel.
Dmitry KorneyevDepartment of Biomedical Engineering, Technion-Israel Institute of Technology, Haifa, 32000, Israel.
Tirosh MeklerDepartment of Biomedical Engineering, Technion-Israel Institute of Technology, Haifa, 32000, Israel.
Sumaya KaiyalDepartment of Biotechnology Engineering, Braude College of Engineering, Karmiel, 2161002, Israel.
Iris Sonia WeitzDepartment of Biotechnology Engineering, Braude College of Engineering, Karmiel, 2161002, Israel.
Netanel KorinDepartment of Biomedical Engineering, Technion-Israel Institute of Technology, Haifa, 32000, Israel.ORCID 0000-0001-7244-889X

Funding

H2020 European Research Council 101002057The Braude Seed Research Fund
6 · The paper itself

Abstract

Injectable hydrogels are promising biomaterials for treating aneurysms, life-threatening blood-filled saccular lesions, enabling complete filling of the aneurysm and supporting tissue repair. Yet, the challenge is to enable clinical translation as hydrogels must not protrude into the parent vessel, nor migrate from the aneurysm cavity. Here, injectable, negatively-charged, biologically and mechanically compatible hydrogels with environment-sensitive swelling capabilities that cease swelling upon contact with blood are developed. Hydrogels are fabricated by copolymerizing sodium 2-acrylamido-2-methylpropanesulfonic acid (NaAMPS) and 3-sulfopropyl acrylate (KSPA) by using polyethylene glycol diacrylate (PEGDA). Three formulations (2%, 4%, and 6%) demonstrating a wide range of physiological-relevant stiffnesses are fabricated. The selected mechano-compatible 4% hydrogel exhibits a suitable swelling pressure (125 kPa) and supports high endothelial cell viability (> 75%). Importantly, the hydrogel demonstrates a significant differential swell with respect to blood (30 ± 4%), plasma (58 ± 3%), and PBS (82 ± 2%). This environment-selective swelling, upon exposure to blood, results in minimal directional swelling toward the parent artery, which can improve embolization outcomes. Hydrogel embolization in 3D-printed aneurysm models subjected to physiological blood flow shows no protrusion toward the main artery while completely blocking flow into the aneurysm. This approach provides promising opportunities for efficient embolization of a variety of aneurysms and vascular malformations.

Indexed as

AneurysmBiomimetic MaterialsEmbolization, TherapeuticGlycosaminoglycansHydrogelsAnimalsCell SurvivalHumansHuman Umbilical Vein Endothelial CellsPolyethylene GlycolsGlycosaminoglycansHydrogelspoly(ethylene glycol)diacrylatePolyethylene Glycolsaneurysmembolizationinjectable hydrogelsminimally invasive therapyswelling pressure

Identifiers

PMID40192445
PMCPMC12232164

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.